



Tyrosine Kinase Inhibitors for Lung Cancer

Guest Editor:

Dr. In-Jae Oh

Department of Internal Medicine,
Lung and Esophageal Cancer
Clinic, Chonnam National
University Hwasun Hospital,
Jeonnam, Republic of Korea

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Dear Colleagues,

Precision oncology has fundamentally changed the diagnosis and treatment of cancer. Driver mutations are essential for carcinogenesis as well as tumor progression as they confer a selective growth advantage to cancer cells. Identification of driver mutations in growth-related protein kinases, especially tyrosine kinases has led to the clinical development of an array of tyrosine kinase inhibitors (TKIs) in various malignancies, including lung cancer. In recent decades, there has been a significant development in the management of patients with oncogene-addicted advanced-stage non-small cell lung cancer. For example, inhibition of epidermal growth factor receptors and anaplastic lymphoma kinase tyrosine kinases have proven to be of meaningful clinical benefit. An improved understanding of tyrosine kinase biology has also led to faster drug development, identification of resistance mechanisms and ways to overcome resistance.

This Special Issue will highlight the efficacy, toxicity and resistance mechanism of TKIs in patients with lung cancer.

Dr. In-Jae Oh
Guest Editor





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI